Treatment Patterns, Socioeconomic Status and Clinical Burden in Mild COPD: A Swedish Real-World, Retrospective Cohort Study, the ARCTIC Study

References

• Global strategy for the diagnosis M, and prevention of chronic obstructive pulmonary disease, global initiative for chronic obstructive lung disease 2021 report. Available from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf. Accessed May 5, 2021.
   Google Scholar
• Sundblad BM, Larsson K, Nathell L. Low awareness of COPD among physicians. Clin Respir J. 2008;2(1):11–16. doi:10.1111/j.1752-699X.2007.00020.x
   PubMed Web of Science ®Google Scholar
• Welte T, Vogelmeier C, Papi A. COPD: early diagnosis and treatment to slow disease progression. Int J Clin Pract. 2015;69(3):336–349. doi:10.1111/ijcp.12522
   PubMed Web of Science ®Google Scholar
• Lindberg A, Bjerg A, Ronmark E, Larsson LG, Lundback B. Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med. 2006;100(2):264–272. doi:10.1016/j.rmed.2005.04.029
   PubMed Web of Science ®Google Scholar
• Barrecheguren M, Gonzalez C, Miravitlles M. What have we learned from observational studies and clinical trials of mild to moderate COPD? Respir Res. 2018;19(1):177. doi:10.1186/s12931-018-0882-0
   PubMed Web of Science ®Google Scholar
• Kruis AL, Stallberg B, Jones RC, et al. Primary care COPD patients compared with large pharmaceutically-sponsored COPD studies: an UNLOCK validation study. PLoS One. 2014;9(3):e90145. doi:10.1371/journal.pone.0090145
   PubMed Web of Science ®Google Scholar
• Singh D, D’Urzo AD, Donohue JF, Kerwin EM. Weighing the evidence for pharmacological treatment interventions in mild COPD; a narrative perspective. Respir Res. 2019;20(1):141. doi:10.1186/s12931-019-1108-9
   PubMed Web of Science ®Google Scholar
• Janson C, Johansson G, Stallberg B, et al. Identifying the associated risks of pneumonia in COPD patients: arctic an observational study. Respir Res. 2018;19(1):172. doi:10.1186/s12931-018-0868-y
   PubMed Web of Science ®Google Scholar
• Larsson K, Janson C, Stallberg B, et al. Impact of COPD diagnosis timing on clinical and economic outcomes: the Arctic observational cohort study. Int J Chron Obstruct Pulmon Dis. 2019;14:995–1008. doi:10.2147/COPD.S195382
   PubMed Web of Science ®Google Scholar
• Lisspers K, Larsson K, Janson C, et al. Gender differences among Swedish COPD patients: results from the Arctic, a real-world retrospective cohort study. NPJ Prim Care Respir Med. 2019;29(1):45. doi:10.1038/s41533-019-0157-3
   PubMed Web of Science ®Google Scholar
• Lisspers K, Larsson K, Johansson G, et al. Economic burden of COPD in a Swedish cohort: the Arctic study. Int J Chron Obstruct Pulmon Dis. 2018;13:275–285. doi:10.2147/COPD.S149633
   PubMed Web of Science ®Google Scholar
• Stallberg B, Janson C, Larsson K, et al. Real-world retrospective cohort study Arctic shows burden of comorbidities in Swedish COPD versus non-COPD patients. NPJ Prim Care Respir Med. 2018;28(1):33. doi:10.1038/s41533-018-0101-y
   PubMed Web of Science ®Google Scholar
• Socialstyrelsen; 2017. Available from: http://www.socialstyrelsen.se/register. Accessed January 07 2021.
   Google Scholar
• Lamprecht B, Soriano JB, Studnicka M, et al. Determinants of underdiagnosis of COPD in national and international surveys. Chest. 2015;148(4):971–985. doi:10.1378/chest.14-2535
   PubMed Web of Science ®Google Scholar
• Cai L, Wang XM, Fan LM, Shen JR, Liu YN, Golden AR. Socioeconomic variations in chronic obstructive pulmonary disease prevalence, diagnosis, and treatment in rural Southwest China. BMC Public Health. 2020;20(1):536. doi:10.1186/s12889-020-08687-5
   PubMed Web of Science ®Google Scholar
• Sahni S, Talwar A, Khanijo S, Talwar A. Socioeconomic status and its relationship to chronic respiratory disease. Adv Respir Med. 2017;85(2):97–108. doi:10.5603/ARM.2017.0016
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Evaluation of CLtIPSEI. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa0909883
   PubMed Web of Science ®Google Scholar
• Larsson K, Janson C, Lisspers K, et al. The impact of exacerbation frequency on clinical and economic outcomes in Swedish COPD patients: the Arctic study. Int J Chron Obstruct Pulmon Dis. 2021;16:701–713. doi:10.2147/COPD.S297943
   PubMed Web of Science ®Google Scholar
• Greulich T, Weist BJD, Koczulla AR, et al. Prevalence of comorbidities in COPD patients by disease severity in a German population. Respir Med. 2017;132:132–138. doi:10.1016/j.rmed.2017.10.007
   PubMed Web of Science ®Google Scholar
• Gronseth R, Erdal M, Tan WC, et al. Research teams at c. Unemployment in chronic airflow obstruction around the world: results from the BOLD study. Eur Respir J. 2017;50(3):1700499. doi:10.1183/13993003.00499-2017
   PubMed Web of Science ®Google Scholar
• Rai KK, Adab P, Ayres JG, Jordan RE. Systematic review: chronic obstructive pulmonary disease and work-related outcomes. Occup Med. 2018;68(2):99–108. doi:10.1093/occmed/kqy012
   Google Scholar
• Schwab P, Dhamane AD, Hopson SD, et al. Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis. 2017;12:735–744. doi:10.2147/COPD.S112256
   PubMed Web of Science ®Google Scholar
• Stallberg B, Janson C, Johansson G, et al. Management, morbidity and mortality of COPD during an 11-year period: an observational retrospective epidemiological register study in Sweden (PATHOS). Prim Care Respir J. 2014;23(1):38–45. doi:10.4104/pcrj.2013.00106
   PubMedGoogle Scholar
• Troosters T, Sciurba F, Battaglia S, et al. Physical inactivity in patients with COPD, a controlled multi-center pilot-study. Respir Med. 2010;104(7):1005–1011. doi:10.1016/j.rmed.2010.01.012
   PubMed Web of Science ®Google Scholar
• Van Remoortel H, Hornikx M, Demeyer H, et al. Daily physical activity in subjects with newly diagnosed COPD. Thorax. 2013;68(10):962–963. doi:10.1136/thoraxjnl-2013-203534
   PubMed Web of Science ®Google Scholar
• Van Remoortel H, Hornikx M, Langer D, et al. Risk factors and comorbidities in the preclinical stages of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;189(1):30–38. doi:10.1164/rccm.201307-1240OC
   PubMed Web of Science ®Google Scholar
• Shin KC. Physical activity in chronic obstructive pulmonary disease: clinical impact and risk factors. Korean J Intern Med. 2018;33(1):75–77. doi:10.3904/kjim.2017.387
   PubMed Web of Science ®Google Scholar
• Läkemedelsverket Medical Products Agency (Sweden). Läkemedelverkets expert panel. Farmakologisk behandling av kroniskt obstruktiv lungsjukdom (KOL) - behandlingsrekommendationer; 2015. Available from: https://www.lakemedelsverket.se/sv/. Accessed June 10, 2022.
   Google Scholar
• Martinez FJ, Agusti A, Celli BR, et al. Treatment trials in young patients with COPD and pre-COPD patients: time to move forward. Am J Respir Crit Care Med. 2021;205:275–287.
   Web of Science ®Google Scholar